๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Neoadjuvant Chemoimmunotherapy
Clinical trial register · China

Neoadjuvant Chemoimmunotherapy Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 5 Wuhan 4 Shanghai 4 Hefei 3 Fuzhou 2
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou5 Wuhan4 Shanghai4 Hefei3 Fuzhou2
All 17 locations
Target enrolment
to

Neoadjuvant Chemoimmunotherapy trials in China

12 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Microbiota in Neoadjuvant Chemoimmunotherapy for NSCLC
NCT07752589Non-Small Cell Carcinoma of Lung, Gut Microbiomes, Neoadjuvant Chemoimmunotherapy
Guangdong Provincial People's Hospital
Observational
100
Guangzhou
2026-07-31
Not yet open
Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response
NCT07670715Locally Advanced Non-small Cell Lung Cancer (NSCLC), Thoracic Radiotherapy, Immune Checkpoint Inhibitors, Neoadjuvant Chemoimmunotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2026-07-01
Recruiting
RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
NCT07541521Stage IIB-III NSCLC, Sleeve Lobectomy, Robotic Surgery, Neoadjuvant Chemoimmunotherapy
Shanghai Chest Hospital
Observational
100
Fuzhou, Guangzhou, Shenzhen, Nanjing, Qingdao, Tianjing, Shanghai
2026-04-13
Recruiting
Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
NCT07528066Neoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection, Stage IIB-III NSCLC
Shanghai Chest Hospital
Observational
200
Fuzhou, Guangzhou, Shenzhen, Nanjing, Qingdao, Tianjing, Shanghai
2026-03-02
Not yet open
Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base
NCT07145931Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer, Neoadjuvant Chemoimmunotherapy, Objective Response Rate
Sun Yat-sen University
Phase 2
24
Guangzhou
2025-09-20
Recruiting
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
NCT06288360Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy
Tongji Hospital
Phase 2
40
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Wuhan, Changsha, Shenyang
2024-09-12
Recruiting
Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer
NCT06289751Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Radical Hysterectomy, Extrafascial Hysterectomy
Tongji Hospital
Phase 2
50
Wuhan, Jinan
2024-09-03
Recruiting
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
NCT06289062Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Fertility Preservation
Tongji Hospital
Phase 2
40
Guangzhou, Wuhan
2024-05-08
Recruiting
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
NCT06288373Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant Chemoimmunotherapy
Tongji Hospital
Phase 2/3
440
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Wuhan, Changsha, Shenyang
2024-04-22
Recruiting
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
NCT06056336Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy
Guo Xufeng
Phase 2
73
Shanghai
2023-09-07
Active, closed
Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma
NCT07127497Pathological Complete Response, Rectal Cancer, Neoadjuvant Chemoimmunotherapy
The First Affiliated Hospital of Anhui Medical University
Phase 2
50
Hefei
2022-06-01
Recruiting
Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NCT05740995Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy
Shanghai Zhongshan Hospital
Observational
40
Shanghai
2020-12-01
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/condition/neoadjuvant-chemoimmunotherapy

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 12 of those studies listing the condition Neoadjuvant Chemoimmunotherapy.

How many Neoadjuvant Chemoimmunotherapy trials are recruiting in China?

8 of the 12 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Neoadjuvant Chemoimmunotherapy), 12 studies
PhaseStudiesRecruitingShare
Phase 27458.3%
Observational4333.3%
Phase 2/3118.3%

Most active sponsors

Lead sponsors with the most studies (Neoadjuvant Chemoimmunotherapy)
Lead sponsorStudiesRecruiting
Tongji Hospital44
Shanghai Chest Hospital22
Guangdong Provincial People's Hospital10
Guo Xufeng11
Shanghai Zhongshan Hospital11
Sun Yat-sen University10
The First Affiliated Hospital of Anhui Medical University10
Tianjin Medical University Cancer Institute and Hospital10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.